H.C. Wainwright lowered the firm’s price target on Bionano Genomics (BNGO) to $6 from $7 and keeps a Buy rating on the shares. The firm cites the company’s increased share count for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Bionano Genomics Earnings Call: Margin Gains, Growth Test
- Closing Bell Movers: Core Labs falls after below-consensus pre-announcement
- Bionano Genomics Earnings Update: Did it Beat Estimate Forecasts?
- Bionano Genomics reports Q4 revenue $7.95M vs. $8.16M last year
- Bionano Genomics sees Q1 revenue $6.5M-$6.7M